Paper Details

  1. Home
  2. Paper Details

Clinical Results of Hypomethylating Agents in AML Treatment.

Author: CruijsenMarjan, HulsGerwin, LübbertMichael, WijermansPierre

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Azacitidine and decitabine are DNA methyltransferase inhibitors that are used to treat acute myeloid leukemia (AML). These drugs have shown to be effective in treating older patients and patients with co-morbidities, and they have a relatively mild side effect profile. In clinical trials, azacitidine and decitabine have been shown to be superior to conventional care in older AML patients. These drugs can help to bridge older patients with co-morbidities to the potential curative treatment of allogeneic hematopoietic cell transplantation.
Paper Details　
Original Abstract of the Article :
Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike gene mutations, epigenetic changes are potentially reversible, which makes them attractive for therapeutic intervention. Agents that affect epigenetics are the DNA methyltransferase inhibitors, azaci...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470235/

データ提供：米国国立医学図書館（NLM）

Hypomethylating Agents: A New Dawn for Acute Myeloid Leukemia Treatment

Acute myeloid leukemia (AML), a type of blood cancer, is characterized by abnormal proliferation of immature white blood cells. Epigenetic changes play a significant role in AML development and are potentially reversible, making them attractive targets for therapeutic intervention. This study examines the clinical use of hypomethylating agents, azacitidine and decitabine, in AML treatment. The authors highlight the potential of these agents to alter epigenetic patterns and induce remission in AML patients, particularly those with unfavorable cytogenetic characteristics. The study reviews the results of phase 3 trials demonstrating the superiority of azacitidine and decitabine compared to conventional care for older AML patients who are not eligible for intensive treatment. The authors discuss the promising results of modified treatment schedules, particularly the 10-day decitabine schedule, which has shown significant complete remission rates.

Hypomethylating Agents Offer Hope for AML Patients

The study underscores the significant therapeutic potential of hypomethylating agents, particularly azacitidine and decitabine, in AML treatment. These agents demonstrate efficacy in inducing remission and improving outcomes for patients with AML, particularly those with unfavorable cytogenetic characteristics.

Navigating AML Treatment: A Multifaceted Approach

The study highlights the need for a personalized approach to AML treatment, considering patient-specific factors, including age, overall health, and genetic characteristics. The use of hypomethylating agents as part of a comprehensive treatment plan can offer a more effective and potentially less toxic approach to managing AML.

Dr.Camel's Conclusion

Imagine a camel caravan traversing a desert, seeking a cure for AML. This study, like a guidepost pointing towards a hidden oasis, highlights the potential of hypomethylating agents in combating this devastating disease. These agents, like a refreshing spring in the desert, offer hope for AML patients, offering a new dawn in the fight against this challenging cancer.

Date :
  1. Date Completed 2015-08-04
  2. Date Revised 2020-09-29
Further Info :

Pubmed ID

26237015

DOI: Digital Object Identifier

PMC4470235

Related Literature

Article Analysis
・Side Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.